

ORIGINAL ARTICLE

**COMPARATIVE EFFECTIVENESS OF TWO METRONOMIC
CHEMOTHERAPY SCHEDULES. OUR EXPERIENCE IN THE PRECLINICAL
FIELD**

^{1,§}M. J. Rico, ^{1,§}H. A. Perroud, ^{1,2}L. E. Mainetti, ^{1,3}V. R. Rozados, ^{1,3}O. G. Scharovsky

¹Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Rosario, Argentina

² Present address: Departments of Urology and Pathology, Wayne State University School of Medicine, Detroit, MI, USA

[§]Contributed equally to this work and should both be considered as first authors.

³V. R. Rozados and O. G. Scharovsky contributed equally to this work and should both be considered as senior authors.

CORRESPONDING AUTHOR: Dr. O. Graciela Scharovsky

Santa Fe 3100

(S2002KTR) Rosario, Argentina

TE: + 54-341-4804558/63 Ext: 244

Fax: + 54-341-4804569

e-mail: graciela.scharovsky@gmail.com

ABSTRACT

Metronomic chemotherapy refers to the chronic, equally spaced, delivery of low doses of chemotherapeutic drugs, without extended interruptions. Previously, we developed two combined metronomic schemes for the treatment of murine mammary tumors. The aim of this study was to compare their effects on tumor and metastasis growth, survival and toxicity. Metronomic chemotherapy with Cyclophosphamide + Celecoxib showed higher antimetastatic power than Cyclophosphamide + Doxorubicin, while being similar in other aspects. That difference, plus the advantage that represents its oral administration, points at the election of Cyclophosphamide + Celecoxib combination for the metronomic treatment of mammary tumors.

KEY WORDS

Metronomic chemotherapy, combined treatment, cyclophosphamide, doxorubicin, Celecoxib, mammary adenocarcinomas

INTRODUCTION

Metastatic breast cancer, as most of advanced tumors, remains incurable, and its treatment is limited to palliative management, with the objective to prolong progression free survival, overall survival and provide an acceptable quality of life. The problem of metastatic breast cancer management persists, in spite of having a good response, at least in local stages and despite the inclusion of new targeted agents which usually have a modest impact in therapeutic efficacy (1, 2).

The concept of metronomic chemotherapy (MCT) is well known in the oncology research area. Briefly, it refers to the chronic administration of low doses of chemotherapeutic drugs, at frequent and regular intervals, without extended rest periods, allowing a continuous and chronic treatment for different kinds of tumors, without side effects or severe toxicity (3). Prolonged rest periods, needed after a standard chemotherapy for the recovery of patients from common toxicities, represent an opportunity for specific and resistant cancer cells to re-grow. Those facts underline the importance of avoiding or reducing rest periods. .

Several mechanisms of action like inhibition of angiogenesis, restoration of anti-tumor immune response and induction of tumor dormancy, has been proposed to explain MCT therapeutic effect (4, 5).

Cox-2 plays an important role in carcinogenesis and tumor growth and progression (6-9). This enzyme is frequently expressed in invasive and *in situ* breast cancers (10, 11). The use of Cox-2 inhibitors in cancer therapy has proved to be effective, inhibiting cell proliferation and angiogenesis.

In the same way, Cyclophosphamide, an alkylating agent that has been used for decades and it is presently used in standard chemotherapy, is one of the first and most studied drugs in metronomic or low dose administration settings. Its antiangiogenic and immunomodulating effects were probed in different experimental tumor-models and also in the clinic (3).

Doxorubicin is an anthracycline widely used in cancer chemotherapy, commonly utilized for treating several types of cancers. Different authors found that the metronomic

administration of this drug, alone or in combination with Cy, brings about an antitumor and antimetastatic effect (5, 12, 13).

Considering the high incidence of mammary tumors in humans, we had studied the therapeutic efficacy and the mechanism/s of action of MCT with cyclophosphamide (Cy) as a single drug and combined with Celecoxib (Cel) (14), or with doxorubicin (Dox) (5), in two mouse mammary adenocarcinomas (MA) tumor-models.

The aim of the present work was to compare the results previously obtained on efficacy and toxicity in animals bearing two different MA, treated with two different MCT regimens: Cy+Cel or Cy+Dox.

MATERIALS AND METHODS

Animals.

Inbred BALB/c and CBI female mice were obtained from our breeding facilities. Animals were fed with commercial chow and water *ad libitum* and maintained in a 12-h light/dark cycle. All the experiments were developed during the first half of the light cycle. Tumor-bearing mice were euthanized by CO₂ exposure. The animals were treated in accordance to the Canadian Council on Animal Care guidelines (15).

Drugs.

Cyclophosphamide (Laboratorio Filaxis, SA, Argentina) was dissolved in sterile distilled water at a concentration of 20 mg/ml and diluted in the drinking water to reach 0.12 mg/ml. Drinking water was replaced every other day and the mice's daily Cy intake/kg body weight (BW) was calculated.

Doxorubicin (Laboratorio Filaxis, SA, Argentina) was dissolved in sterile saline immediately before its intraperitoneal injection.

Celecoxib (Pfizer Corp, Chicago, USA) was dissolved in dimethylsulfoxide at a concentration of 200 mg/ml. Immediately before its administration by gavage, it was further diluted with phosphate buffer saline to a concentration of 2 mg/ml (8).

Tumors

The mouse mammary tumors M-234p and M-406, established in our laboratory, were used.

M-234p: Is a type B (16) moderately differentiated mammary adenocarcinoma that shows a mixed pattern and develops lung metastasis. It spontaneously arose in a BALB/c female mouse, and it is maintained *in vivo* by serial subcutaneous passages in syngeneic mice, with 100% of incidence.

M-406: Is a type B semi-differentiated mammary adenocarcinoma which appeared spontaneously in an inbred CBI female mouse. It is maintained *in vivo* by serial intraperitoneal passages in syngeneic mice, with 100% of incidence.

Treatments

A) *MCT Cy+Cel*: Adult BALB/c or CBI female mice were implanted subcutaneously in their right flanks with $\cong 1\text{-mm}^3$ M-234p (I) or M-406 (II) tumor fragments, respectively. Five (for M-234p) or eight (for M-406) days later, when the tumors reached $\cong 150\text{ mm}^3$, the animals were distributed in four groups. ($N=6-7$ and $N=5-6$ /group for M-234p and M-406, respectively) and treated as follows: *Control*: regular drinking water without drug administration; *Cy*: In drinking water ($\cong 30\text{ mg/kg BW/day}$); *Cel*: Oral Cel ($\cong 30\text{ mg/kg p.o.}$), five times/week; *Cy+Cel*: Treatments combined.

B) *MCT Cy+Dox*: Adult BALB/c or CBI mice were implanted s.c. with $\cong 1\text{ mm}^3$ M-234p (I) or M-406 (II) tumor fragments, respectively. Five (M-234p) or eight (M-406) days later, when tumors reached $\cong 150\text{ mm}^3$, animals ($N=5-8$ /group) were distributed and treated as follows: *Control*: regular drinking water without drug administration; *Cy*: in drinking water ($\cong 30\text{ mg/kg BW/day}$); *Dox*: 0.5 mg/kg/BW , i.p. three times/week; *Cy+Dox*: treatments combined.

Antitumor and anti-metastatic effects.

Antitumor effect. Tumor sizes were measured with Vernier calipers, and tumor volumes were calculated as follows: $v = 0.4 (ab^2)$, where $v = \text{volume (mm}^3)$, $a = \text{largest diameter (mm)}$ and $b = \text{smallest diameter}$. Animals were weighed twice/week, and blood samples were obtained on day 0 and days 24 (M-234p) or 25 (M-406) for white blood cell count. When the first animal reached the largest ethically permitted tumor volume (LPV), animals belonging to the four groups were euthanized. For survival studies, in a duplicate experiment, animals were euthanized when each one reached LPV.

Antimetastatic effect. Adult BALB/c and CBI mice were injected intravenously with 5×10^5 M-234p cells and 2×10^5 M-406 cells in 0.1 ml saline, respectively. On day 3, animals were treated as indicated above (MCT Cy+Cel and MCT Cy+Dox). The animals were

controlled daily and weighed twice/week. All the mice were euthanized by the time the first mouse showed signs of metastatic illness. Lungs were excised, weighed, and then fixed in Bouin's solution to determine the number and size of metastatic foci. With both data the total metastatic burden/mouse was calculated.

Treatment comparison.

As we had previously demonstrated that the therapeutic efficacy of the combined treatment groups was significantly higher than that achieved with each individual drug, the data herein analyzed were those belonging to the groups of animals that received MCT with both drugs. For the efficacy comparison we calculated the percentages of reduction with respect to each control group of both, tumor and lung metastatic volumes of each group of combined treatment. In the same way, the percentages of survival increase with respect to controls were also determined and statistically compared.

Statistical analysis

Kruskal–Wallis and Dunn's Multiple Comparison Test were used to examine the differences between groups with GraphPad Prism® version 3.0 (GraphPad Software, San Diego, CA). Differences were considered statistically significant at $P < 0.05$.

RESULTS

As previously informed, both treatments significantly inhibited tumor growth (5, 14). The % of reduction of tumor volume of animals in the combined treated group with respect to control group without treatment [median (range): AI: 84.4 % (30-99.4), AII: 77.9 % (50.9-89.9), BI: 75.5 % (62.5-96.8), BII: 95.6 (57-99.6)] did not differ between treatments or between tumor-models (Kruskal-Wallis non-parametric ANOVA) (Table 1).

Mice that received MCT with Cy+Cel or Cy+Dox, showed a significantly higher survival than the corresponding control mice in both tumor models. When treatments were compared to each other, and interesting effect was observed, while in the M-234p tumor model the Cy + Cel treatment duplicates the survival with respect to the Cy + Dox treatment [AI: 77.6% (5.3–84.2); BI: 36.1% (12.4–113), respectively], on the other hand, in the M-406 tumor model occurred exactly the opposite [AII: 56.5% (–4.3–56.5), BII: 110.9% (60–308.2), respectively]. Because of those discrepancies, the statistical comparison did not reach significance, in spite of being close to it ($P=0.054$) (Table 2).

The lung metastatic burden was found to be diminished in both therapeutic schemes. The % of reduction of lung metastatic volume [AI: 99.7 % (98.7-100), AII: 99.8 % (97.1-99.2), BI: 90 % (48.4-99.3), BII: 90.6 % (35.9-96.6)] was significantly different among all the groups ($P<0.01$); Dunn's post-test showed differences in AI vs BI ($P<0.05$). (Table 3)

The surrogate markers of morbidity/toxicity monitored, namely the motor activity, fur quality, food intake, response to stimuli and breathing, plus the evolution of body weight and total leucocytes count showed no differences with respect to their respective controls, along the experiments, independently of the tumor-models or treatments (Data not shown).

DISCUSSION

The combination of two or more existing chemotherapy agents in order to achieve therapeutic synergism is an interesting goal in most of the metronomic schedules assayed.

A number of authors have studied the therapeutic effect of metronomic chemotherapy in either the pre-clinical or the clinical field, using different drug combinations. Just to mention a few, Cy combined with other agents like anti-VEGFR antibody (17), TNP-470 (18), imatinib (19), peptide ABT-510 (20), tirapazamine (21), cetixumab (22), 5-fluorouracil pro-drug UFT (23), axitinib (24), gemcitabine (25) and celecoxib (26-28). Some of them were developed in tumor-models of mammary adenocarcinomas (18, 21-23, 26). The therapeutic results achieved with the different drugs combinations were variable. Also, those therapeutic schedules were accompanied by the presence or absence of toxic effects. Hence, it is somewhat difficult to identify which is, for a determined type of tumor, the best metronomic drug combination in terms of efficacy and derived toxicity, two properties that in turn, will determine the extension and the quality of life of the tumor bearers.

Following this line of thought we decided to compare the antitumor and the antimetastatic efficacy of the two drug combinations tested in our lab to treat two murine mammary adenocarcinomas.

The antitumor efficacy and the increase in survival did not show statistical differences, either among treatments or tumor-models. On the other hand, the combination of Cy+Cel was superior than Cy+Dox related to antimetastatic power, suggesting its potential use at the adjuvant setting.

In matter of toxicity, both treatments showed low to null toxic effects. No weight losses were detected throughout the experiment in any of the groups of both tumor models. Also, no alterations were found in the markers of morbidity/toxicity monitored (5, 14). Therefore, the quality of life in both combinations would be similar. Nevertheless, if we take into consideration that the administration of Cy+Cel is exclusively oral, while the

Cy+Dox schedule has the drawback of the Dox intraperitoneal injection, the scale tilts into the Cy+Cel direction.

The statistical comparison we made allows us to choose the Cy+Cel treatment as the best of our MCT treatments. But, what about the different schedules and combinations tested by other researchers in other models? Are they better, similar or worse, in efficacy and toxicity, than that achieved with our treatment? Which one would be the better choice to translate to the clinic? Speaking particularly about mammary adenocarcinoma treatment, it would be of interest that other authors calculate their own percentages of decrease in tumor and metastasis volume and the percentages of survival increase with respect to controls. The availability of such data would enable to compare different schedules and combinations of MCT for mammary tumors for their translation to the clinic.

In the meantime, in the clinical field, metronomic Cy+Cel schedule for treating advanced breast cancer patients is being tested, showing a good response and low to null toxicity (26).

In conclusion, although both combined metronomic treatments were fairly similar respect to the absence of toxicity and to the inhibition of tumor growth, leading to an increased survival, the election of the Cy+Cel combination as the better one, was based in its antimetastatic power and also because of the advantage that represents its oral administration. The last one is not a minor advantage, since the development of these oral chemotherapies allows an effective treatment with an easy drug administration, with less significant adverse effects, providing better outpatient management without the emotional burden that intravenous chemotherapy represents.

ACKNOWLEDGEMENTS

Work in O.G.S. laboratory is supported by grants from National University of Rosario (Argentina). O.G.S. is a member of the scientific career of the Research Council of the National University of Rosario (CIUNR, Argentina).

FUNDING

This work was supported by National University of Rosario [1MED210 to O.G.S.; 1MED283 to O.G.S.].

DISCLOSURE

The authors have declared no conflicts of interest

REFERENCES

1. Vogel C. L., Nabholz J. M. Monotherapy of metastatic breast cancer: a review of newer agents. *Oncologist* **1999**,*4*,17-33.
2. Vogel C. L., Cobleigh M. A., Tripathy D., Gutheil J. C., Harris L. N., Fehrenbacher L., Slamon D. J., Murphy M., Novotny W. F., Burchmore M., Shak S., Stewart S. J. First-line Herceptin monotherapy in metastatic breast cancer. *Oncology* **2001**,*61 Suppl 2*,37-42.
3. Scharovsky O. G., Mainetti L. E., Rozados V. R. Metronomic chemotherapy: changing the paradigm that more is better. *Curr Oncol* **2009**,*16*,7-15.
4. Pasquier E., Kavallaris M., Andre N. Metronomic chemotherapy: new rationale for new directions. *Nat Rev Clin Oncol* **2010**,*7*,455-65.
5. Mainetti L. E., Rico M. J., Fernandez-Zenobi M. V., Perroud H. A., Roggero E. A., Rozados V. R., Scharovsky O. G. Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas. *Ann Oncol* **2013**.
6. Masferrer J. Approach to angiogenesis inhibition based on cyclooxygenase-2. *Cancer J* **2001**,*7 Suppl 3*,S144-50.
7. Masferrer J. L. Cyclooxygenase-2 inhibitors in cancer prevention and treatment. *Adv Exp Med Biol* **2003**,*532*,209-13.
8. Basu G. D., Pathangey L. B., Tinder T. L., Lagioia M., Gendler S. J., Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. *Mol Cancer Res* **2004**,*2*,632-42.
9. Kerbel R. S., Kamen B. A. The anti-angiogenic basis of metronomic chemotherapy. *Nat Rev Cancer* **2004**,*4*,423-36.
10. Taromaru G. C., VM D. E. Oliveira, Silva M. A., Montor W. R., Bagnoli F., Rinaldi J. F., Aoki T. Interaction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: A new field for prevention and treatment. *Oncol Lett* **2012**,*3*,682-8.
11. Wang D., Dubois R. N. Cyclooxygenase-2: a potential target in breast cancer. *Semin Oncol* **2004**,*31*,64-73.
12. Shiraga E., Barichello J. M., Ishida T., Kiwada H. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model. *Int J Pharm* **2008**,*353*,65-73.
13. Dellapasqua S., Mazza M., Rosa D., Ghisini R., Scarano E., Torrisi R., Maisonneuve P., Viale G., Cassano E., Veronesi P., Luini A., Goldhirsch A., Colleoni M. Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. *Breast* **2011**,*20*,319-23.
14. Mainetti L. E., Rozados V. R., Rossa A., Bonfil R. D., Scharovsky O. G. Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas. *J Cancer Res Clin Oncol* **2011**,*137*,151-63.
15. Care (CCAC) Canadian Council on Animal. Guidelines on procurement of animals used in science. **2007**, Ottawa, Canada. CCAC.
16. Squartini F., Pingitore R. Tumours of the mammary gland. 1994/01/01 ed1994.
17. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D. J., Bohlen P., Kerbel R. S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. *J Clin Invest* **2000**,*105*,R15-24.
18. Browder T., Butterfield C. E., Kraling B. M., Shi B., Marshall B., O'Reilly M. S., Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. *Cancer Res* **2000**,*60*,1878-86.

19. Pietras K., Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. *J Clin Oncol* **2005**,*23*,939-52.
20. Yap R., Veliceasa D., Emmenegger U., Kerbel R. S., McKay L. M., Henkin J., Volpert O. V. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. *Clin Cancer Res* **2005**,*11*,6678-85.
21. Emmenegger U., Morton G. C., Francia G., Shaked Y., Franco M., Weinerman A., Man S., Kerbel R. S. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. *Cancer Res* **2006**,*66*,1664-74.
22. du Manoir J. M., Francia G., Man S., Mossoba M., Medin J. A., Vilorio-Petit A., Hicklin D. J., Emmenegger U., Kerbel R. S. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. *Clin Cancer Res* **2006**,*12*,904-16.
23. Munoz R., Man S., Shaked Y., Lee C. R., Wong J., Francia G., Kerbel R. S. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. *Cancer Res* **2006**,*66*,3386-91.
24. Ma J., Waxman D. J. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. *Mol Cancer Ther* **2008**,*7*,79-89.
25. Shevchenko I., Karakhanova S., Soltek S., Link J., Bayry J., Werner J., Umansky V., Bazhin A. V. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. *Int J Cancer* **2013**,*133*,98-107.
26. Perroud H. A., Rico M. J., Alasino C. M., Queralt F., Mainetti L. E., Pezzotto S. M., Rozados V. R., Scharovsky O. G. Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. *Future Oncol* **2013**,*9*,451-62.
27. Fontana A., Galli L., Fioravanti A., Orlandi P., Galli C., Landi L., Bursi S., Allegrini G., Fontana E., Di Marsico R., Antonuzzo A., D'Arcangelo M., Danesi R., Del Tacca M., Falcone A., Bocci G. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. *Clin Cancer Res* **2009**,*15*,4954-62.
28. Buckstein R., Kerbel R. S., Shaked Y., Nayar R., Foden C., Turner R., Lee C. R., Taylor D., Zhang L., Man S., Baruchel S., Stempak D., Bertolini F., Crump M. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. *Clin Cancer Res* **2006**,*12*,5190-8.

TUMOR	PERCENTAGE OF TUMOR VOLUME REDUCTION (median-range)	
	A. Cy + Cel	B. Cy + Dox
I. M-234p	84,4 % (30-99.4)	75.5 % (62.5-96.8)
II. M-406	77.9 % (50,9-89,9)	95.6 % (57-99.6)

Table 1. Percentage of reduction of tumor volume with respect to control group. ANOVA (Kruskal-Wallis): N.S.

TUMOR	PERCENTAGE OF SURVIVAL INCREASE (median-range)	
	A. Cy + Cel	B. Cy + Dox
I. M-234p	77.6 % (5.3-84,2)	36.1 % (12.4-113)
II. M-406	56.5 % (-4.3-56,5)	110.9 % (60-308.2)

Table 2. Percentage of survival increase with respect to control group. ANOVA (Kruskal-Wallis):
P=0.054

TUMOR	PERCENTAGE OF LUNG METASTATIC BURDEN REDUCTION (median-range)	
	A. Cy + Cel	B. Cy + Dox
I. M-234p	99.7 % (98.7-100)	90 % (48.4-99.3)
II. M-406	99.8 % (97.1-99.2)	90,6 % (35.9-96.6)

Table 3. Percentage of reduction of lung metastatic burden with respect to control group. ANOVA (Kruskal-Wallis): $P < 0.01$; I. M-234p: Cy+Cel vs Cy+ Dox, $P < 0.05$ (Dunn's Multiple Comparison Test)